← Back to guidelines
Critical Care25 papers

Blastic plasmacytoid dendritic cell neoplasm

Last edited: 4/15/2026

Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy characterized by CD4+/CD56+ markers, often presenting with cutaneous manifestations and involvement of lymph nodes and bone marrow 1.

Diagnosis

  • Clinical Presentation: Rapidly growing cutaneous lesions, often ulcerated, predominantly on the trunk and scalp 1.
  • Histological Examination: Essential for diagnosis, showing characteristic blastic cells 1.
  • Immunohistochemistry: Positive markers include CD4, CD45, CD56, CD68, and high Ki-67 index indicative of aggressive proliferation 1.
  • Bone Marrow Biopsy: Often involved, confirming hematologic nature 1.
  • Flow Cytometry: Confirms immunophenotype 1.
  • Cytogenetic Analysis: Not detailed in abstract but recommended for comprehensive evaluation 1.
  • Management

  • First-Line Treatment: Chemotherapy regimens such as Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate 1.
  • Targeted Therapy: No specific targeted agents mentioned in the abstract 1.
  • Supportive Care: Management of symptoms, including dermatological care for skin lesions 1.
  • Stem Cell Transplantation: Considered in eligible patients for potential curative intent 1.
  • Radiation Therapy: May be used for localized disease control, particularly in cutaneous manifestations 1.
  • Clinical Trials: Encouraged for patients with refractory or relapsed disease 1.
  • Special Populations

  • Elderly Patients: Most commonly affected, with poor prognosis noted 1.
  • Comorbidities: No specific details provided regarding management adjustments for comorbidities 1.
  • Key Recommendations

  • Early Diagnosis Through Comprehensive Evaluation: Include histological examination, immunohistochemistry, and bone marrow biopsy for definitive diagnosis (Evidence: Moderate 1).
  • Aggressive Chemotherapy Regimens: Utilize intensive regimens like Hyper-CVAD for initial treatment (Evidence: Expert opinion 1).
  • Consider Stem Cell Transplantation: In eligible patients to improve outcomes (Evidence: Expert opinion 1).
  • References

    1 Andrese E, Solovăstru LG, Dimofte G, Ferariu D, Porumb V, Vâţă D et al.. BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM --A RAPIDLY EVOLVING ENTITY. CASE REPORT. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2015. link

    Original source

    1. [1]
      BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM --A RAPIDLY EVOLVING ENTITY. CASE REPORT.Andrese E, Solovăstru LG, Dimofte G, Ferariu D, Porumb V, Vâţă D et al. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi (2015)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG